Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/jcp.v63n0312d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Electroconvulsive Therapy-Induced Mania in Bipolar Disorder: A Case Report.
Cureus
December 2024
Psychiatry, Psychiatrisch Ziekenhuis Asster, Sint-Truiden, BEL.
Electroconvulsive therapy (ECT) is widely recognized as a safe and effective intervention for treating severe affective episodes in patients with bipolar disorder. However, it can sometimes precipitate unexpected manic phases in patients treated for a depressive episode, a phenomenon known as ECT-induced mania. While this occurrence is recognized, it remains poorly understood and minimally addressed in the literature.
View Article and Find Full Text PDFLong-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.
J Child Adolesc Psychopharmacol
January 2025
Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.
Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.
View Article and Find Full Text PDFResponses to clinical treatment of bipolar versus unipolar depressive episodes in women versus men.
J Psychopharmacol
November 2024
International Consortium for Mood and Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, MA, USA.
Background: Whether responses to treatment of major depressive episodes differ between women and men or with bipolar (BD) and major depressive disorders (MDD) remains unresolved.
Aims: To test for diagnostic and sex differences in responses to treatment of depression.
Methods: We compared changes in the 21-item Hamilton Depression Rating Scale (HDRS) ratings of depression ( = 3243) between women (64.
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
J Clin Psychiatry
October 2024
Yale Depression Research Program, Department of Psychiatry at the Yale School of Medicine and the Yale Psychiatric Hospital, New Haven, Connecticut.
Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression treated with ketamine/ esketamine in a real-world setting.
View Article and Find Full Text PDFFull-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data.
J Affect Disord
December 2024
US Medical Affairs, AbbVie, Florham Park, NJ, United States. Electronic address:
Introduction: Patients with bipolar I disorder may experience mood destabilization or treatment-emergent affective switch (TEAS) from one symptom pole to the other spontaneously or following treatment. Optimal treatment should address symptoms from both poles without precipitating destabilization.
Methods: These were pooled post hoc analyses of data from randomized, double-blind, placebo-controlled studies of cariprazine 3-12 mg/d for bipolar I mania (NCT00488618, NCT01058096, NCT01058668) and cariprazine 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!